Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC
Medical experts explore the advantages and disadvantages of next-generation sequencing testing, highlighting the disparities in the quantity of tissue samples being sent for analysis, which can lead to inconclusive results when insufficient sample sizes are provided.
Video Player is loading.
EP: 1.Patient Case 1: A 62-Year-Old Female with NSCLC
EP: 2.Systemic Treatment Options for Non-Small Cell Lung Cancer
EP: 3.Counseling Patients and Caregivers on NSCLC Treatment Toxicities
EP: 4.Patient Case 2: A 45-Year-Old Man with NSCLC Stage IV with Bone and Liver Metastases
EP: 5.Patient Case 3: A 34-Year-Old Non-Smoker with Stage IIIA NSCLC
EP: 6.Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural Metastases
Now Viewing
EP: 7.Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC
EP: 8.Closing Thoughts on the Future of NSCLC
EP: 9.Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
Recent Videos
BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status
The Future of DLBCL: Innovations in Therapy and Patient Care
Overview of BESPOKE Patient Characteristics
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
